| Product Name | Pertuzumab ELISA Kit |
|---|---|
| Synonyms | OMNITARG, rhuMAB 2C4, CAS: 380610-27-5 |
| Method | Quantitative |
| Detection Range | 0.31-5 μg/mL |
| Sensitivity | 0.156 μg/ml |
| Sample Types | Plasma, Serum |
| Reconstitution | Detection method: Colorimetric. Recovery: 80-120%. Specifications: Pertuzumab |
| Storage | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
| Notes | Detection method: Colorimetric. Recovery: 80-120% |
| Background | Pertuzumab (also called 2C4, trade name Perjeta) is a humanized (from mouse) monoclonal antibody (mAb) used in combination with trastuzumab and docetaxel for the treatment of metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer. It was discovered and developed by Genentech, a subsidiary of Roche, and was first approved in 2012. It is manufactured recombinantly in Chinese hamster ovary (CHO) cells. The monoclonal antibody 2C4 appears to have first been published in 1990 by scientists from Genentech. By 2003 Genentech understood that 2C4 prevented HER2 dimerizing with other HER receptors and had begun Phase I trials, aiming for a broad range of cancers, not just one’s overexpressing HER2. It was the first known HER dimerization inhibitor. In 2005 Genentech presented poor results of Phase II trials of pertuzumab as a single agent in prostate, breast, and ovarian cancers, and said that it intended to continue developing it in combination with other drugs for ovarian cancer. In 2007 Genentech dropped the trade name Omnitarg. In 2012 the results were published of the CLEOPATRA trial, a randomized placebo-controlled Phase III trial of pertuzumab in combination with trastuzumab and docetaxel in HER2-positive metastatic breast cancer. Pertuzumab received US Food and Drug Administration (FDA) approval for the treatment of HER2-positive metastatic breast cancer later that year. The FDA approved the neoadjuvant indication in 2013. Pertuzumab was approved in Europe in 2013. |
| Supplier | ARP |
All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
